financetom
Business
financetom
/
Business
/
TIMELINE-From Altman's departure to Musk's lawsuit: the OpenAI saga
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
TIMELINE-From Altman's departure to Musk's lawsuit: the OpenAI saga
Mar 8, 2024 4:59 PM

(Adds latest developments)

March 8 (Reuters) - OpenAI CEO Sam Altman will return to

the ChatGPT-maker's board along with three new directors, the

company said on Friday.

Below is a timeline of the events in a tumultuous few months

for the artificial intelligence company.

Date Event

Nov. 17, OpenAI board fires CEO Sam Altman and

2023 President Greg Brockman quits. Mira Murati

named as interim CEO

Nov. 18, Altman's firing was over a "breakdown in

2023 communication between Sam and the board," and

not "malfeasance", COO Brad Lightcap says in

an internal memo

Early investor Khosla Ventures says it wants

Altman back at OpenAI, "but will back him in

whatever he does next"

Altman discusses a possible return to the

company even as he contemplates a new venture,

source says

Nov. 20, Microsoft CEO Satya Nadella says the Windows

2023 maker has hired Altman, Brockman and their

colleagues to lead a new advanced AI research

team

OpenAI appoints former Twitch boss Emmett

Shear as interim CEO. Shear pledges probe into

Altman's exit.

Nearly all OpenAI staff threaten to quit and

join Altman at Microsoft, demanding board

resign and Altman and Brockman are reinstated

Some investors in OpenAI explore legal

recourse against the board, sources say

Nov. 21, OpenAI says Altman will return as CEO with a

2023 new initial board. Brockman will also return

Nov. 22, Ahead of Altman's exit, staff wrote a letter

2023 to the board warning of an AI discovery that

could threaten humanity, sources say

Nov. 29, Altman says Microsoft will take a non-voting,

2023 observer position on OpenAI's board

Dec. 8, 2023 Britain's anti-trust regulator considers

whether Microsoft's partnership with OpenAI

has resulted in the creation of a relevant

merger situation. Microsoft denies it has

taken control of the company

Dec. 13, Axel Springer partners with OpenAI in a

2023 first-of-its-kind deal that will deliver

summaries of the global news publisher's

content in response to ChatGPT queries

Dec. 27, The New York Times sues OpenAI and

2023 Microsoft, accusing them of using the

newspaper's articles without permission to

train chatbots

Jan. 9, 2024 EU antitrust regulators say Microsoft's ( MSFT )

financial backing for OpenAI may be subject to

the bloc's merger rules

Jan. 25, The FTC orders OpenAI, Microsoft, Alphabet

2024 , Amazon and Anthropic to

provide information on recent investments and

partnerships as it scrutinizes tech deals

Feb. 16, OpenAI completes a deal that values it at $80

2024 billion or more, according to media reports

Feb. 27, OpenAI asks a federal judge to dismiss parts

2024 of the NYT copyright lawsuit against it,

arguing that the newspaper "hacked" ChatGPT

and other AI systems to generate misleading

evidence

Feb. 29, The SEC is scrutinizing internal

2024 communications by Altman as part of an

investigation into whether the company's

investors were misled, WSJ reports

March 1, Elon Musk sues OpenAI and Altman, saying they

2024 abandoned the startup's original mission to

develop AI for the benefit of humanity

March 8, Altman will return to the OpenAI board along

2024 with three new directors, the company says

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Akoya Biosciences Secures Exclusive License for NeraCare's Immunoprint Test
Akoya Biosciences Secures Exclusive License for NeraCare's Immunoprint Test
Dec 10, 2024
09:03 AM EST, 12/10/2024 (MT Newswires) -- Akoya Biosciences ( AKYA ) said Tuesday that it has signed an exclusive global license agreement with NeraCare to develop and commercialize the Immunoprint test on Akoya's multiplexed immunofluorescent platform. The agreement grants Akoya rights to develop and market the test for clinical research, diagnostic development, or patient testing following regulatory approval, Akoya...
Google invests in Intersect Power in over $800 million funding round amid AI race
Google invests in Intersect Power in over $800 million funding round amid AI race
Dec 10, 2024
(Reuters) - Alphabet's Google, along with TPG Rise Climate and other investors, is backing clean energy developer Intersect Power as part more than $800 million funding round, the company said on Tuesday. Google's capital investment in Intersect Power comes as the tech giant, like other hyperscalers including Microsoft and Meta, races to bolster its domestic data center capacity to meet...
Google invests in Intersect Power in over $800 mln funding round amid AI race
Google invests in Intersect Power in over $800 mln funding round amid AI race
Dec 10, 2024
Dec 10 (Reuters) - Alphabet's Google, along with TPG Rise Climate and other investors, is backing clean energy developer Intersect Power as part more than $800 million funding round, the company said on Tuesday. Google's capital investment in Intersect Power comes as the tech giant, like other hyperscalers including Microsoft ( MSFT ) and Meta, races to bolster its domestic...
Ferguson's Fiscal First-Quarter Earnings Fall Annually as Sales Miss Market Expectations
Ferguson's Fiscal First-Quarter Earnings Fall Annually as Sales Miss Market Expectations
Dec 10, 2024
09:02 AM EST, 12/10/2024 (MT Newswires) -- Ferguson's (FERG) fiscal first-quarter earnings declined on an annual basis and sales fell short of Wall Street estimates amid continued weakness in certain commodity categories while the company reiterated its full-year revenue growth outlook. The UK-based plumbing and heating products company on Tuesday posted adjusted earnings of $2.45 per share, down from $2.65...
Copyright 2023-2026 - www.financetom.com All Rights Reserved